CLINICAL TRIALS PROFILE FOR TABRECTA
✉ Email this page to a colleague
All Clinical Trials for TABRECTA
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05567055 ↗ | Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations | Not yet recruiting | Novartis | Phase 2 | 2022-12-01 | This is a phase II single-arm open label trial to evaluate the intracranial efficacy of capmatinib in advanced stage NSCLC with asymptomatic BM with positive MET amplification or METΔex14 detected on cfDNA. |
NCT05567055 ↗ | Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations | Not yet recruiting | Timothy Burns | Phase 2 | 2022-12-01 | This is a phase II single-arm open label trial to evaluate the intracranial efficacy of capmatinib in advanced stage NSCLC with asymptomatic BM with positive MET amplification or METΔex14 detected on cfDNA. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TABRECTA
Condition Name
Clinical Trial Locations for TABRECTA
Trials by Country
Clinical Trial Progress for TABRECTA
Clinical Trial Phase
Clinical Trial Sponsors for TABRECTA
Sponsor Name